Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 4/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522262 | 0.84 | CHEK1 (0.47) | MAPTKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL16236688 | 0.80 | LRRK2 (0.43) | ABL1GRM5LRRK2 | |
| SCHEMBL16236512 | 0.80 | HTR6 (0.45) | MEN1ALDH1A1HPGDKMT2APIK3CD | |
| SCHEMBL16237017 | 0.80 | ABL1 (0.49) | ABL1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16236051 | 0.80 | ABL1 (0.49) | ABL1PIK3CDGRM5PIK3CAPIK3CB | |
| SCHEMBL16254764 | 0.80 | POLB (0.45) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16236452 | 0.77 | MAP4K4 (0.47) | RETABL1GRM5LRRK2PIK3CA | |
| SCHEMBL16254863 | 0.77 | TNNI3K (0.50) | — | |
| SCHEMBL16236077 | 0.77 | KDR (0.47) | ABL1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16236903 | 0.77 | KDR (0.46) | ABL1ALDH1A1AAK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | claimed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | claimed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | HAVCR2, NR4A3, NR2C2 | RET 1627/4885ABL1 4171/4885MAPT 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.